Byterna Therapeutics completed its angel plus round financing, exclusively invested by Efung Capital. Proceeds will accelerate Investigator Initiated Trial (IIT) clinical research on the circular mRNA (cmRNA) in vivo CAR‑T pipeline BR101. Founded in June 2023, Byterna is an AI‑driven biopharma focused on cmRNA‑based immunotherapy, leveraging circular mRNA and targeted tLNP technologies.
Contents
Transaction Overview
| Item | Details |
|---|---|
| Financing Round | Angel Plus |
| Lead Investor | Efung Capital (exclusive) |
| Use of Proceeds | Accelerate IIT clinical research on cmRNA in vivo CAR‑T pipeline BR101 |
| Company Founded | June 2023 |
| Technology Focus | AI‑driven circular mRNA and targeted tLNP for immunotherapy |
Technology Platform & Achievements
| Technology | Capability |
|---|---|
| Seamless Circularization | Efficient cmRNA production with high circularization rates |
| AI Sequence Design | AI‑optimized sequences for stability and expression |
| Chemical Modification | Enhanced cmRNA stability and reduced immunogenicity |
| In Vivo Targeted Delivery | tLNP targeting T cells for in vivo CAR‑T generation |
| Circular mRNA CAR Design | Proprietary design and evaluation platform |
| Platform Status | Globally leading cmRNA in vivo CAR‑T development platform |
Pipeline & Development
| Pipeline | Stage | Indication |
|---|---|---|
| BR101 (cmRNA CAR‑T) | IIT clinical research | Undisclosed oncology target |
| Additional Pipelines | Multiple in vivo CAR‑T programs | Advanced preclinical/IND‑enabling |
| Core Pipeline | Advancing rapidly to clinical research | cmRNA CAR‑T platform |
Market Opportunity & Strategic Implications
- Market Size: Global CAR‑T market $7 billion (2025); in vivo CAR‑T segment projected to reach $5 billion by 2033 with cmRNA advantages
- Technology Differentiation: In vivo CAR‑T eliminates ex vivo manufacturing; cmRNA offers stability vs. linear mRNA; tLNP targeting enables cell‑specific delivery
- For Byterna: Angel plus funding validates platform; IIT data will support IND filing and potential Series A; exclusive Efung backing provides strategic guidance
- For Investors: Early‑stage exposure to next‑generation CAR‑T; cmRNA platform has platform potential beyond oncology; AI‑driven design reduces development risk
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Byterna’s clinical development timeline, market potential, and financing plans. Actual results may differ due to clinical risks, competitive dynamics, or regulatory challenges.-Fineline Info & Tech
